Drug Discovery

Adverse Drug Reactions (ADRs) are a leading cause of morbidity and mortality. Existing prediction methods rely mainly on chemical similarity, machine learning on structured databases, or isolated target profiles, but often fail to integrate heterogeneous, partly unstructured evidence effectively. We present a knowledge graph-based framework that unifies diverse sources, drug-target data (ChEMBL), clinical trial literature (PubMed), trial metadata (ClinicalTrials.gov), and post-marketing safety reports (FAERS) into a single evidence-weighted bipartite network of drugs and medical conditions. Applied to 400 protein kinase inhibitors, the resulting network enables contextual comparison of efficacy (HR, PFS, OS), phenotypic and target similarity, and ADR prediction via target-to-adverse-event correlations. A non-small cell lung cancer case study correctly highlights established and candidate drugs, target communities (ERbB, ALK, VEGF), and tolerability differences. Designed as an orthogonal, extensible analysis and search tool rather than a replacement for current models, the framework excels at revealing complex patterns, supporting hypothesis generation, and enhancing pharmacovigilance. Code and data are publicly available at https://github.com/davidjackson99/PKI_KG.

Deep generative modeling to stochastically design small molecules is an emerging technology for accelerating drug discovery and development. However, one major issue in molecular generative models is their lower frequency of drug-like compounds. To resolve this problem, we developed a novel framework for optimization of deep generative models integrated with a D-Wave quantum annealing computer, where our Neural Hash Function (NHF) presented herein is used both as the regularization and binarization schemes simultaneously, of which the latter is for transformation between continuous and discrete signals of the classical and quantum neural networks, respectively, in the error evaluation (i.e., objective) function. The compounds generated via the quantum-annealing generative models exhibited higher quality in both validity and drug-likeness than those generated via the fully-classical models, and was further indicated to exceed even the training data in terms of drug-likeness features, without any restraints and conditions to deliberately induce such an optimization. These results indicated an advantage of quantum annealing to aim at a stochastic generator integrated with our novel neural network architectures, for the extended performance of feature space sampling and extraction of characteristic features in drug design.

We introduce AceFF, a pre-trained machine learning interatomic potential (MLIP) optimized for small molecule drug discovery. While MLIPs have emerged as efficient alternatives to Density Functional Theory (DFT), generalizability across diverse chemical spaces remains difficult. AceFF addresses this by refining the TensorNet2 architecture and training it on a comprehensive dataset of drug-like compounds. This approach yields a force field that balances high-throughput inference speed with DFT-level accuracy. We introduce two models sharing the same architecture: \mbox{AceFF-2}, trained on our own dataset of small molecules and supporting the essential medicinal chemistry elements (H, B, C, N, O, F, Si, P, S, Cl, Br, I); and \mbox{AceFF-2-OMOL}, trained on a subset of OMol25 containing the AceFF-2 elements plus the common biomolecular ion elements Na and K. The models are explicitly trained to handle charged states. Validation against rigorous benchmarks, including complex torsional energy scans, molecular dynamics trajectories, batched minimizations, and tests of force and energy accuracy, demonstrates that AceFF is state-of-the-art for organic molecules in the accuracy and speed regime important for drug discovery. The AceFF-2 and AceFF-2-OMol model weights and inference code are available at https://huggingface.co/Acellera/AceFF-2.0 and https://huggingface.co/Acellera/AceFF-2-OMOL.

Molecule generation from extremely limited training data is a key challenge in drug discovery. Existing fragment-based methods are more suitable than atom-based approaches in this regime, but typically optimize fragment selection separately from downstream generation. Expert feedback is also especially valuable with limited data, yet translating such feedback into model objectives usually requires AI engineering expertise. We introduce FRAGMENTA, an end-to-end framework for small-data drug lead optimization with two components: (1) LVSEF, a fragment-based generator that jointly optimizes fragmentation and generation through a tabular reward-update mechanism, and (2) an agentic system that converts conversational expert feedback into updated generative objectives. Across three small-data datasets (11--104 molecules), LVSEF outperforms state-of-the-art methods in the smallest-data settings, matches them at larger scales, and trains ${\sim}16\times$ faster. On three public protein targets, iterative closed-loop optimization improves final-round discovery yield by up to ${\sim}16$ over one-shot LVSEF-only on kinase, with gains depending on how well feedback matches target chemistry. In a real-world cancer drug-discovery deployment, Human-Agent FRAGMENTA identified nearly twice as many molecules with favorable docking scores ($< -6$) as baseline methods.

Many molecular Transformers lack probabilistic latent variables for posterior inference and latent interpolation. We introduce STAR-VAE, a SELFIES-encoded, Transformer-based, AutoRegressive Variational AutoEncoder combining a bidirectional encoder with an autoregressive decoder pretrained on 79 million PubChem molecules. A property signal jointly conditions the prior, posterior, and decoder, while LoRA adapters support fine-tuning on small datasets without modifying the backbone. STAR-VAE achieves 100% validity and near-perfect novelty under unconditional MOSES sampling, the lowest KL divergence on five of ten GuacaMol descriptors, Spearman \r{ho} = 0.62 at 98% validity for synthetic-accessibility conditioning, and directional docking-score control for three Tartarus protein targets. Across four ChEMBL targets, seed-based posterior sampling recovers target-associated held-out scaffolds while label-conditioned sampling produces structurally diverse outputs. Code is available at https://github.com/BiomedSciAI/STAR-VAE.

Make-on-demand combinatorial synthesis libraries (CSLs) like Enamine REAL have significantly enabled drug discovery efforts. However, their large size presents a challenge for virtual screening, where the goal is to identify the top compounds in a library according to a computational objective (e.g., optimizing docking score) subject to computational constraints under a limited computational budget. For current library sizes -- numbering in the tens of billions of compounds -- and scoring functions of interest, a routine virtual screening campaign may be limited to scoring fewer than 0.1% of the available compounds, leaving potentially many high scoring compounds undiscovered. Furthermore, as constraints (and sometimes objectives) change during the course of a virtual screening campaign, existing virtual screening algorithms typically offer little room for amortization. We propose the approximate-but-exhaustive search protocol for CSLs, or APEX. APEX utilizes a neural network surrogate that exploits the structure of CSLs in the prediction of objectives and constraints to make full enumeration on a consumer GPU possible in under a minute, allowing for exact retrieval of approximate top-k sets. To demonstrate APEX's capabilities, we develop a benchmark CSL comprised of more than 10 million compounds, all of which have been annotated with their docking scores on five medically relevant targets along with physicohemical properties measured with RDKit such that, for any objective and set of constraints, the ground truth top-k compounds can be identified and compared against the retrievals from any virtual screening algorithm. We show APEX's consistently strong performance both in retrieval accuracy and runtime compared to alternative methods.

Chemical Language Models (CLMs) are increasingly used in de novo drug design, driven by recent growth in model scale, compute, and dataset size. However, the relationship between design choices, training dynamics, and downstream generation quality remains poorly understood. We present a compute-controlled scaling study of CLMs comprising more than 30,000 experiments across molecular representations (SMILES, SELFIES, SAFE), tokenizations (atom-level and byte-pair encoding), model scales (0.5M-1B parameters), leakage-controlled datasets (MOSES, ChEMBL, PubChem, ZINC-22), and architectures (decoder-only and encoder-decoder). By fitting IsoFLOP profiles, we establish clear scaling trends in pretraining loss, but find that these improvements do not translate into comparable gains in goal-directed molecular design. Layer-wise probing and sparse autoencoder analysis reveal continued development of chemical representations: chemical syntax saturates early, while semantic properties emerge more slowly and become increasingly accessible with further training and model scale. These representational gains coexist with diminishing improvements in goal-directed generation under the evaluated protocols and oracle budgets. Our resulting suite of models, NovoMolGen, achieves state-of-the-art results, outperforming prior CLMs and specialized generative models in goal-directed molecular generation across drug discovery tasks. These findings expose a disconnect between chemical representation learning and downstream molecular design, motivating the development of pretraining paradigms that more directly learn chemical semantics.

Recent advances in large language models have demonstrated considerable potential in scientific domains such as drug repositioning. However, their effectiveness remains constrained when reasoning extends beyond the knowledge acquired during pretraining. Conventional approaches, such as fine-tuning or retrieval-augmented generation, face limitations in either imposing high computational overhead or failing to fully exploit structured scientific data. To overcome these challenges, we propose DrugMCTS, a novel framework that synergistically integrates RAG, multi-agent collaboration, and Monte Carlo Tree Search for drug repositioning. The framework employs five specialized agents tasked with retrieving and analyzing molecular and protein information, thereby enabling structured and iterative reasoning. Extensive experiments on the DrugBank and KIBA datasets demonstrate that DrugMCTS achieves substantially higher recall and robustness compared to both general-purpose LLMs and deep learning baselines. Our results highlight the importance of structured reasoning, agent-based collaboration, and feedback-driven search mechanisms in advancing LLM applications for drug repositioning.

Explainable artificial intelligence approaches accelerate drug discovery by improving molecular representation learning, identifying key molecular structures, and rationalizing drug property prediction. However, developing end-to-end explainable models for target-specific structure-activity relationship modeling remains challenging because compound-protein interaction data are often limited for individual targets, and small changes in chemical substituents or local structural motifs can cause large differences in molecular properties. Therefore, effectively leveraging structural and property information to identify key moieties associated with compound-protein affinity is essential. We propose a graph neural network (GNN) framework that uses property and structural information from activity-cliff molecule pairs targeting specific proteins to predict compound-protein affinity, measured by half-maximal inhibitory concentration (IC50), and explain property differences. To improve explainability, we trained GNNs with structure-aware loss functions using group lasso and sparse group lasso regularization, which prune and highlight molecular subgraphs relevant to activity differences. We applied this framework to activity-cliff data from molecules targeting six tyrosine-protein kinases across the Src, Abl, and Tec families, as well as anaplastic lymphoma kinase. Integrating common- and uncommon-node information with sparse group lasso improved target-specific molecular property prediction, producing lower root mean square errors and higher Pearson correlation coefficients. Regularization also enhanced GNN feature attribution by improving graph-level global direction scores and atom-level coloring accuracy. These results support more interpretable drug discovery pipelines, particularly for identifying critical molecular substructures during lead optimization.

Deep learning-based antimicrobial peptide (AMP) discovery faces critical challenges such as limited controllability, lack of representations that efficiently model antimicrobial properties, and low experimental hit rates. To address these challenges, we introduce OmegAMP, a framework designed for reliable AMP generation with increased controllability. Its diffusion-based generative model leverages a novel conditioning mechanism to achieve fine-grained control over desired physicochemical properties and to direct generation towards specific activity profiles, including species-specific effectiveness. This is further enhanced by a biologically informed encoding space that significantly improves overall generative performance. Complementing these generative capabilities, OmegAMP leverages a novel synthetic data augmentation strategy to train classifiers for AMP filtering, drastically reducing false positive rates and thereby increasing the likelihood of experimental success. Our in silico experiments demonstrate that OmegAMP delivers state-of-the-art performance across key stages of the AMP discovery pipeline, enabling us to achieve an unprecedented success rate in wet lab experiments. We tested 25 candidate peptides, 24 of them (96%) demonstrated antimicrobial activity, proving effective even against multi-drug resistant strains. Our findings underscore OmegAMP's potential to significantly advance computational frameworks in the fight against antimicrobial resistance.

Predicting clinical outcomes from preclinical data is essential for selecting safe and effective drug combinations and for reducing late-stage failures. AI models use molecular structure and target annotations, and do not leverage the perturbation readouts that report how a compound acts in a cellular context. Here we introduce Madrigal, a multimodal AI model that learns from structural, pathway, cell-viability, and transcriptomic data. Madrigal aligns these modalities across 21,842 compounds into a shared latent space and predicts combination outcomes even for drugs observed in only a subset of the data modalities. Trained on 158 expert-curated and 795 patient-reported combination outcomes, Madrigal outperforms single-modality and state-of-the-art multimodal methods. Ablations show that modality alignment and multimodal input each improve predictive performance. Madrigal predicts elevated risk for combinations that share membrane transporters. In head-to-head trials that compare two combination arms,the arm with the higher observed incidence of neutropenia, anemia, alopecia, or hypoglycemia receives the higher predicted risk in 25 of 28 comparisons. In MASH, Madrigal ranks resmetirom among the candidates with favorable predicted safety when paired with type 2 diabetes drugs. Madrigal also improves adverse-event prediction in a longitudinal patient cohort and an independent oncology cohort and predicts efficacy in primary acute myeloid leukemia samples and patient-derived xenografts.

Background: Neurosymbolic (NeSy) artificial intelligence describes the combination of logic or rule-based techniques with neural networks. Compared to neural approaches, NeSy methods often possess enhanced interpretability, which is particularly promising for biomedical applications like drug discovery. However, no clear guidelines exist to assess the biological plausibility of model interpretations. Methods: To assess interpretability in the context of drug discovery, we devise a novel prediction task, called drug mechanism-of-action (MoA) deconvolution, with an associated, tailored knowledge graph (KG), MoA-net. We then develop the MoA Retrieval System (MARS), a NeSy approach for drug discovery which leverages logical rules with learned rule weights. Results: Using MARS' interpretable features alongside domain knowledge, we find that MARS and other NeSy approaches on KGs are susceptible to reasoning shortcuts, in which the prediction of true labels is driven by ``degree-bias'' rather than the domain-based rules. Subsequently, we demonstrate ways to identify and mitigate this. Thereafter, MARS achieves performance on par with current state-of-the-art models while producing model interpretations aligned with known MoAs. Conclusion: Through MARS, we showcase the novel task of computational MoA deconvolution. Our results emphasize the importance of using interpretable models, like NeSy ones, for applications in drug discovery. Specifically, by identifying and mitigating reasoning shortcuts, MARS MoA predictions which are biologically meaningful and, therefore, more reliable for downstream drug discovery research.

Workflows in drug-target interaction (DTI) assessment require integrating heterogeneous data from predictive models, curated resources, and observations from experimental literature. This evidence can be incomplete or conflicting. DrugAgent is a large language model (LLM)-based multi-agent system focused on DTI evidence integration that integrates outputs from machine learning, knowledge graph, and retrieval-augmented generation (RAG) agents. DrugAgent converts agent outputs into interpretable representations, then summarizes conflict across the evidence. We evaluated DrugAgent on kinase screening data of 900 pairs spanning 178 kinases and 42 inhibitors, and an androgen receptor antagonist screening benchmark. On the kinase dataset, LLM-as-a-Judge evaluation indicated outputs were faithful to input evidence in 98.8% of cases. Biological plausibility of returned summarization was high (scores 3-4 out of 5) across ground-truth classes: 79% of Weak activity labels cases (81% for Moderate/77% Strong); Strong cases received higher scores than Weak/Moderate. Label stability showed 98% agreement across runs. Results on the antagonist benchmark were consistent with the kinase dataset. Retrieved literature provided the greatest benefit when direct drug-target evidence was available, highlighting the importance of evidence availability for RAG-based integration. DrugAgent provides heterogeneous evidence-grounded DTI assessment, complementing standalone DTI prediction. We provide strategies to model agreement, conflict, and uncertainty in biomedical evidence integration. Code: https://github.com/sciluna/DrugAgent.

Molecular optimization, the process of designing molecules with desirable properties, represents a critical challenge in drug discovery. The recent advancements in large language models (LLMs) have opened new opportunities for their integration with traditional molecular optimization algorithms to improve performance. In this work, we propose Molecular Language Model powered Evolutionary Algorithm (Mol-E), an evolutionary algorithm that relies on the generative capabilities of LLMs trained on molecules and molecular properties. Scientific Contribution. Mol-E obtains the highest aggregate Top-10 AUC among the comparable full-23-task results considered here, scoring 17.500 in the task-agnostic regime, in which the oracle is treated strictly as a black box, and 20.551 in the task-informed regime, in which the optimizer receives a fixed semantic description of the objective. Mol-E also improves over the evaluated baselines on multi-property optimization with docking against DRD2, MK2, and AChE.